ArticleArchives of gynecology and obstetrics2025
Development and validation of a predictive model for preeclampsia: a retrospective cohort study.
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeWe conduct this study to develop and validate a predictive nomogram for preeclampsia (PE) to inform the development of early intervention strategies in clinical practice.
methodsIn this analysis, we collected data from women with medium or high risk for PE who underwent placental growth factor (PlGF)-based testing between December 20, 2021 and December 31, 2022. The gestational age at the time of taking the PlGF-based test for the PE and non-PE groups was 20.0 weeks (range 16.1-26.1 weeks) and 22.2 weeks (range 16.2-27.3 weeks), respectively. The independent risk factors for PE were identified through both univariate and multivariate analyses. Based on these independent risk factors, a logistic regression model for risk prediction was developed. The model was validated using five-fold cross-validation. Moreover, the efficacy of the model was appraised using the area under the receiver operating characteristic curve (AUROC), while the calibration of the model was assessed through calibration curves. Additionally, decision curves and clinical impact curves were leveraged to evaluate the clinical applicability of the model.
resultsIn total, 2063 women were included. Of these, 108 had PE. Body mass index, mean arterial pressure, a ratio of soluble fms-like tyrosine kinase-1/PlGF, history of adverse pregnancy, family history of PE, previous history of PE, chronic hypertension, autoimmune disease, and polycystic ovary syndrome were independent risk factors for PE. The model constructed based on independent risk factors demonstrated that the AUROC in the training set was 0.883 (95% confidence interval [CI] 0.838-0.928), with a sensitivity of 0.827 and specificity of 0.816. In the validation set, the AUROC was 0.862 (95% CI 0.774-0.951), with a sensitivity of 0.815 and specificity of 0.772. The decision curve revealed that the model had a large probability interval for the net benefit threshold.
conclusionThe predictive nomogram for PE constructed based on common interpretable features has desirable efficacy, which informs the development of specialized preventive protocols in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.